Evaluating Progression Free Survival and Response Outcomes

This segment presents the primary efficacy results of LITESPARK-011. The combination of belzutifan and lenvatinib demonstrated a statistically significant improvement in progression-free survival compared with cabozantinib, with a median benefit of approximately four months. The hazard ratio indicated a meaningful reduction in the risk of disease progression. Objective response rates were also higher with the combination therapy, supporting its increased antitumor activity. While overall survival data were not yet statistically significant, numerical trends favored the combination arm. The discussion highlights that the study met its primary endpoint, representing an important advance in the post–PD-(L)1 treatment setting. The speakers note that these findings provide evidence for a new therapeutic option but also raise questions about how best to integrate the regimen into existing treatment sequences.